Le Min1, Anand Vaidya, Carolyn Becker. 1. Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Abstract
OBJECTIVE: To present a case series of ipilimumab-related secondary adrenal insufficiency. METHODS: In this cases series, we review the presentation, evaluation, diagnosis, and management of patients with advanced melanoma who received ipilimumab and were referred to our endocrinology clinic for evaluation of hormonal abnormalities. RESULTS: Seven patients presented with symptoms, signs, or biochemical evidence of adrenal insufficiency 6 to 12 weeks after starting ipilimumab therapy. Ipilimumab is a cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody that is approved for the treatment of metastatic melanoma and has widespread use for this disease. All 7 patients had biochemical evidence of profound secondary adrenal insufficiency. Thyroid function abnormalities, central hypogonadism, and low insulinlike growth factor 1 levels were seen in a subset of patients. Only 2 patients had abnormal findings on pituitary magnetic resonance imaging. Posterior pituitary function remained normal. CONCLUSIONS: Our findings suggest that the enhanced immune response associated with ipilimumab therapy may have a predilection for corticotroph and possibly thyrotroph cells. We recommend periodic hypothalamic-pituitary-adrenal axis monitoring for patients on this therapy.
OBJECTIVE: To present a case series of ipilimumab-related secondary adrenal insufficiency. METHODS: In this cases series, we review the presentation, evaluation, diagnosis, and management of patients with advanced melanoma who received ipilimumab and were referred to our endocrinology clinic for evaluation of hormonal abnormalities. RESULTS: Seven patients presented with symptoms, signs, or biochemical evidence of adrenal insufficiency 6 to 12 weeks after starting ipilimumab therapy. Ipilimumab is a cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody that is approved for the treatment of metastatic melanoma and has widespread use for this disease. All 7 patients had biochemical evidence of profound secondary adrenal insufficiency. Thyroid function abnormalities, central hypogonadism, and low insulinlike growth factor 1 levels were seen in a subset of patients. Only 2 patients had abnormal findings on pituitary magnetic resonance imaging. Posterior pituitary function remained normal. CONCLUSIONS: Our findings suggest that the enhanced immune response associated with ipilimumab therapy may have a predilection for corticotroph and possibly thyrotroph cells. We recommend periodic hypothalamic-pituitary-adrenal axis monitoring for patients on this therapy.
Authors: Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough Journal: Nature Date: 2003-04-30 Impact factor: 49.962
Authors: Vernon K Sondak; Keiran S M Smalley; Ragini Kudchadkar; Seden Grippon; Peter Kirkpatrick Journal: Nat Rev Drug Discov Date: 2011-06 Impact factor: 84.694
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Joseph A Blansfield; Kimberly E Beck; Khoi Tran; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Suzanne L Topalian; Leah R Haworth; Catherine Levy; Steven A Rosenberg; Richard M Sherry Journal: J Immunother Date: 2005 Nov-Dec Impact factor: 4.456
Authors: Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg Journal: Clin Cancer Res Date: 2007-11-02 Impact factor: 12.531
Authors: Le Min; Frank Stephen Hodi; Anita Giobbie-Hurder; Patrick A Ott; Jason J Luke; Hilary Donahue; Meredith Davis; Rona S Carroll; Ursula B Kaiser Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: Sunita M C De Sousa; Nisa Sheriff; Chau H Tran; Alexander M Menzies; Venessa H M Tsang; Georgina V Long; Katherine T T Tonks Journal: Pituitary Date: 2018-06 Impact factor: 4.107
Authors: Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min Journal: Endocr Rev Date: 2019-02-01 Impact factor: 19.871